Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 134 posts found.

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

June 22, 2018
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …

News
opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

News

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

News

AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer

May 25, 2018
Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

News
astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

News
merckwindow_web

Keytruda success continues, beating Opdivo in lung cancer survival

April 17, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

News
msd

Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression

April 10, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News
pfizer-building-logo1web

Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer

January 19, 2018
Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

News

Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs

January 16, 2018
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …

News
shutterstock_212432119

Moffitt scientists discover new applications for Novartis’s Zykadia

October 11, 2017
Research and Development Cancer, Moffitt, NSCLC, ceritinib, lung cancer, zykadia

Through the use of molecular screening, functional proteomics and computer-based modelling, researchers from the Moffitt Cancer Center have been working …

News
astrazeneca-sign

AstraZeneca’s Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC

October 9, 2017
Sales and Marketing AstraZeneca, Cancer, NSCLC, immunotherapy, lung cancer

AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso beats standard of care in halting NSCLC

September 11, 2017
Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical

AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …

News
novartis_headquarters

Novartis gains first-line approval for Zykadia in lung cancer

June 29, 2017
Research and Development EMA, European Commission, NSCLC, Novartis

The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026